Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LSI-205
- Development stage
- Preclinical
- Lead developer
- LipoSeuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LSI-205 is a liposomal reformulation of a generic oncology small molecule drug currently in development by LipoSeuticals. Part of a pipeline of liposomal-encapsulated chemotherapeutics, LSI-205 is designed for intravenous administration to treat various cancers. The specific active pharmaceutical ingredient (API) for LSI-205 has not been publicly disclosed by the developer, though it is categorized within their oncology portfolio alongside other reformulated generics such as irinotecan (LSI-201) and docetaxel (LSI-202). The goal of the LSI-205 program is to leverage liposomal delivery to enhance the efficacy and reduce the toxicity of the underlying small molecule agent by optimizing its pharmacokinetic profile and biodistribution.
Beyond the preview
Go deeper on LSI-205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LSI-205.